Citi analyst Joanne Wuensch raised the firm’s price target on Integer (ITGR) to $145 from $130 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITGR:
- Integer resumed with an Overweight at Wells Fargo
- Ultralife completes acquisition of Electrochem Solutions for $50M in cash
- Integer completes sale of Electrochem business to Ultralife
- Integer price target raised to $140 from $125 at Piper Sandler
- Integer Holdings Announces Leadership Changes and Strong Q3 Results